Efficacy, Safety, and Patient-Reported Outcomes in Patients with Moderate-to-Severe Plaque Psoriasis Treated with Brodalumab for 5 Years in a Long-Term, Open-Label, Phase II Study

BACKGROUND: Chronic inflammatory diseases such as psoriasis require treatment options that maintain efficacy and tolerability during extended treatment. OBJECTIVE: The aim of the study was to assess the long-term efficacy and safety of brodalumab, a fully human anti-interleukin-17 receptor A monoclo...

Descripción completa

Detalles Bibliográficos
Autores principales: Lebwohl, Mark G., Blauvelt, Andrew, Menter, Alan, Papp, Kim A., Guenthner, Scott, Pillai, Radhakrishnan, Israel, Robert J., Jacobson, Abby
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Springer International Publishing 2019
Materias:
Original Research Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6872506/
https://www.ncbi.nlm.nih.gov/pubmed/31493163
http://dx.doi.org/10.1007/s40257-019-00466-2

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6872506/
https://www.ncbi.nlm.nih.gov/pubmed/31493163
http://dx.doi.org/10.1007/s40257-019-00466-2

Ejemplares similares